6533b7d1fe1ef96bd125c267
RESEARCH PRODUCT
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives
Marco GalloPasqualino MalandrinoGiuseppe FanciulliFrancesca RotaAntongiulio FaggianoAnnamaria ColaoAnnamaria ColaoManuela AlbertelliVito AmorosoEmanuela ArvatGiuseppe BadalamentiEmilio BajettaRoberto BaldelliAntonio BianchiGerardo BottiRoberto BuzzoniDavide CampanaCarlo CarnaghiGiacomo CartenìSara CingarliniLuisa CircelliVittorio ColantuoniJorgelina CoppaFrancesco CorcioneMaria Vittoria DavGaetano De RosaEttore Degli UbertiMarialaura Del Basso De CaroAntonella Di SarnoMassimo FalconiPiero FerollaDiego FeroneFrancesco FioreGermano GaudenziCarla GiordanoDario GiuffridaErika Maria GrossrubatscherElia GuadagnoValentina GuarnottaFrancesco IzzoAndrea LaniaSecondo LastoriaSilvana LeoFabio Lo CalzoFrancesco LogolusoMarco ManzoniMassimo MarchettiChiara MartiniErika MessinaMassimo MilioneRoberta ModicaVincenzo MontesarchioPietro MutoOscar NappiElena NazzariFrancesco PanzutoAnna PiaAlessandro PiovesanGenoveffa PizzaAlfredo PontecorviSara PuscedduPaola RazzoreFerdinando RiccardiGuido RindiConcetta SciammarellaFrancesca SpadaSalvatore TafutoAnnibale VersariGiovanni VitaleMaria Chiara Zatellisubject
0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugdescription
urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies, and five registered clinical trials. Moreover, we analyzed the content of four wide-spread international guidelines. Conclusions Our critical review confirms the lack of high-quality data to recommend everolimus as the first line therapy for pNETs. The ongoing clinical trials reported in this review will hopefully help clinicians, in the near future, to better evaluate the role of everolimus as the first line therapy for pNETs. However, at the moment, there is already enough evidence to recommend everolimus as the first line therapy for patients with symptomatic malignant unresectable insulin-secreting pNETs, to control the endocrine syndrome regardless of tumour growth.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 | Journal of Cancer Research and Clinical Oncology |